Patents by Inventor Thorsten Mutzke
Thorsten Mutzke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210040473Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).Type: ApplicationFiled: July 21, 2020Publication date: February 11, 2021Applicant: CureVac Real Estate GmbHInventors: Andreas FUNKNER, Stefanie DORNER, Stefanie SEWING, Johannes KAMM, Norbert BROGHAMMER, Thomas KETTERER, Thorsten MUTZKE
-
Publication number: 20210030683Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: ApplicationFiled: June 18, 2020Publication date: February 4, 2021Applicant: CureVac AGInventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
Publication number: 20200383922Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: ApplicationFiled: August 17, 2020Publication date: December 10, 2020Applicant: CureVac Real Estate GmbHInventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
-
Publication number: 20200383919Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: ApplicationFiled: August 20, 2020Publication date: December 10, 2020Applicant: CureVac AGInventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
Publication number: 20200318097Abstract: The present invention relates to methods for purifying RNA by chromatography under high salt conditions, e.g. by hydrophobic interaction chromatography.Type: ApplicationFiled: November 28, 2017Publication date: October 8, 2020Inventors: Andreas FUNKNER, Stefanie SEWING, Isabel STROBEL, Thorsten MUTZKE
-
Patent number: 10780054Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: GrantFiled: April 15, 2016Date of Patent: September 22, 2020Assignee: CureVac Real Estate GmbHInventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
-
Patent number: 10760070Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).Type: GrantFiled: May 30, 2016Date of Patent: September 1, 2020Assignee: CureVac Real Estate GmbHInventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
-
Publication number: 20200246451Abstract: The present invention relates to a method for producing a liquid composition comprising a nanoparticle comprising at least one RNA and at least one cationic or polycationic compound, advantageously on a large scale suitable for pharmaceutical applications. The present invention further concerns the use of the inventive method in the manufacture of a medicament or a vaccine. Furthermore, the invention relates to compositions containing the RNA-comprising nanoparticle, and to pharmaceutical compositions comprising the same.Type: ApplicationFiled: April 2, 2020Publication date: August 6, 2020Applicant: CureVac Real Estate GmbHInventors: Thorsten MUTZKE, Markus KREUZ, Stefanie SEWING, Fabian Johannes EBER, Wenke WAGNER, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
Patent number: 10729654Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: May 20, 2016Date of Patent: August 4, 2020Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 10653768Abstract: The present invention relates to a method for producing a liquid composition comprising a nanoparticle comprising at least one RNA and at least one cationic or polycationic compound, advantageously on a large scale suitable for pharmaceutical applications. The present invention further concerns the use of the inventive method in the manufacture of a medicament or a vaccine. Furthermore, the invention relates to compositions containing the RNA-comprising nanoparticle, and to pharmaceutical compositions comprising the same.Type: GrantFiled: April 13, 2016Date of Patent: May 19, 2020Assignee: CureVac Real Estate GmbHInventors: Thorsten Mutzke, Markus Kreuz, Stefanie Sewing, Fabian Johannes Eber, Wenke Wagner, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Publication number: 20200060971Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: ApplicationFiled: November 11, 2019Publication date: February 27, 2020Applicant: CureVac AGInventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
Patent number: 10517827Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: GrantFiled: May 20, 2016Date of Patent: December 31, 2019Assignee: CureVac AGInventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewig, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Publication number: 20190133950Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: ApplicationFiled: May 20, 2016Publication date: May 9, 2019Inventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWIG, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
A METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION
Publication number: 20180298372Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).Type: ApplicationFiled: May 30, 2016Publication date: October 18, 2018Inventors: Andreas FUNKNER, Stefanie DORNER, Stefanie SEWING, Johannes KAMM, Norbert BROGHAMMER, Thomas KETTERER, Thorsten MUTZKE -
Publication number: 20180243219Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: ApplicationFiled: April 15, 2016Publication date: August 30, 2018Inventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
-
Publication number: 20180214537Abstract: The present invention relates to a method for producing a liquid composition comprising a nanoparticle comprising at least one RNA and at least one cationic or polycationic compound, advantageously on a large scale suitable for pharmaceutical applications. The present invention further concerns the use of the inventive method in the manufacture of a medicament or a vaccine. Furthermore, the invention relates to compositions containing the RNA-comprising nanoparticle, and to pharmaceutical compositions comprising the same.Type: ApplicationFiled: April 13, 2016Publication date: August 2, 2018Inventors: Thorsten MUTZKE, Markus KREUZ, Stefanie SEWING, Fabian Johannes EBER, Wenke WAGNER, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
Publication number: 20180147146Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.Type: ApplicationFiled: May 20, 2016Publication date: May 31, 2018Inventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWIG, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
Publication number: 20170182081Abstract: The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of RNA and mRNA. The inventive solution exhibits a positive effect on stabilization of the nucleic acid (sequence) during lyophilization and storage but also leads to a considerable increase of the transfection efficiency of a nucleic acid. It thus also increases in vivo expression of a protein encoded by such a nucleic acid upon increased transfection rate. The present invention is furthermore directed to a method of lyophilization using the mannose-containing solution, to pharmaceutical compositions, vaccines, kits, first and second medical uses applying such a mannose-containing solution and/or a nucleic acid (sequence) lyophilized or resuspended with such a solution.Type: ApplicationFiled: March 7, 2017Publication date: June 29, 2017Applicant: CureVac AGInventor: Thorsten MUTZKE
-
Patent number: 9616084Abstract: The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of RNA and mRNA. The inventive solution exhibits a positive effect on stabilization of the nucleic acid (sequence) during lyophilization and storage but also leads to a considerable increase of the transfection efficiency of a nucleic acid. It thus also increases in vivo expression of a protein encoded by such a nucleic acid upon increased transfection rate. The present invention is furthermore directed to a method of lyophilization using the mannose-containing solution, to pharmaceutical compositions, vaccines, kits, first and second medical uses applying such a mannose-containing solution and/or a nucleic acid (sequence) lyophilized or resuspended with such a solution.Type: GrantFiled: September 22, 2014Date of Patent: April 11, 2017Assignee: CureVac AGInventor: Thorsten Mutzke
-
Publication number: 20150141498Abstract: The present invention is directed to (the use of) a solution containing at least one nucleic acid (sequence) and free mannose for lyophilization, transfection and/or injection, particularly of RNA and mRNA. The inventive solution exhibits a positive effect on stabilization of the nucleic acid (sequence) during lyophilization and storage but also leads to a considerable increase of the transfection efficiency of a nucleic acid. It thus also increases in vivo expression of a protein encoded by such a nucleic acid upon increased transfection rate. The present invention is furthermore directed to a method of lyophilization using the mannose-containing solution, to pharmaceutical compositions, vaccines, kits, first and second medical uses applying such a mannose-containing solution and/or a nucleic acid (sequence) lyophilized or resuspended with such a solution.Type: ApplicationFiled: September 22, 2014Publication date: May 21, 2015Applicant: CUREVAC GMBHInventor: Thorsten MUTZKE